Acquisition ImpactThe acquisition is expected to have a low single-digit negative impact on operating profit growth.
Drug Sales PerformanceInsulin sales underperformed slightly, while the obesity portfolio saw significant misses, with Wegovy and Saxenda sales dropping.
Share Buyback ProgramThe planned share buyback is lower than expected due to higher capital expenditures, potentially concerning investors seeking direct returns.